Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07218211 · ClinicalTrials.gov registry record · Phase 4

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

A Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis, sponsored by Duke University.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT07218211 is a Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis that is actively recruiting participants, run by Duke University. The registered enrollment target is 100 participants, below the 379-participant average among 32 other HIV Prevention trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07218211, a Phase 4 study of HIV Prevention and HIV Pre-exposure Prophylaxis, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.

Interventions

  • DRUG Lenacapavir long-acting

Study Locations (1)

North Carolina

  • El Centro Hispano - Durham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-01-13
Est. Completion 2028-01-05
Phase Phase 4

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT07218211

The ClinicalTrials.gov registry entry for NCT07218211 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 32 other HIV Prevention trials with a reported enrollment target (74% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with HIV Prevention appearing as the primary indexed condition, and to 1 intervention - of which Lenacapavir long-acting is the first listed.

NCT07218211 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT07218211 about?

NCT07218211 is a clinical study titled "Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP". The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavi...

What is the current status of trial NCT07218211?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-01-13. Estimated completion is 2028-01-05.

What conditions does trial NCT07218211 study?

This clinical trial studies the following conditions: HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program, HIV Prevention and Care, HIV Pre-exposure Prophylaxis Use.

What interventions are being tested in trial NCT07218211?

The interventions under investigation include: Lenacapavir long-acting (DRUG).

Who is sponsoring clinical trial NCT07218211?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07218211 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.